Sensitive skin is now one of the most common skin concerns, affecting nearly 70 per cent of people worldwide. Sensitive skin cases have increased dramatically in 20 years, raising questions about the impact of modern lifestyles and environmental changes.
Galderma has been actively studying this trend through its Global Sensitive Skin Faculty, which is a group of leading dermatology experts. Their work highlights how everyday factors can influence skin health. A global survey of 17,000 people shows how widespread sensitive skin is and highlights the need for region-specific care.
Galderma’s new research will not only study how common sensitive skin is but will also find out practical solutions, like hydroxy acid formulations. It also examines how sensitive skin differs biologically from conditions such as rosacea. These insights will help doctors improve diagnosis and treatment options for patients.
Tackling itch and atopic conditions with innovation
Itch is more than just an uncomfortable symptom. It can be a life-changing problem for people with chronic skin conditions like atopic dermatitis and prurigo nodularis. Galderma’s monoclonal antibody therapy, Nemluvio® (nemolizumab), is proving to be a promising new option.
Recent studies explain how Nemluvio works in the body. They also show lasting improvements in itch and skin lesions for up to two years. These findings strengthen its role as a promising frontline treatment option for moderate-to-severe AD and PN.
By targeting the biological pathways behind itch, this research goes beyond symptom relief. It offers the possibility of durable disease control, opening new avenues for improving patient quality of life.
Advancing science through collaboration
Equally important is Galderma’s commitment to education and collaboration. The company is organising symposia, industry hubs, and expert-led sessions for dermatologists worldwide. These platforms help them exchange ideas, share experiences, and explore new treatment approaches for skin conditions.
This approach combines strong research, new therapies, and professional education. It positions Galderma as a product leader and a driver of progress in dermatology.
Looking forward
With skin health increasingly shaped by modern living, the need for evidence-driven solutions has never been greater. Galderma is advancing sensitive skin research, creating new treatment options for atopic conditions, and encouraging collaboration in the clinical community. This shows its leadership in dermatology and dedication to improving patient outcomes worldwide.